Research & Development (R&D)

See the following -

An Overview Of The "Patent Trolls" Debate

Brian T. Yeh | Congressional Research Service | August 20, 2012

Congress has recently demonstrated significant ongoing interest in litigation by “patent assertion entities” (PAEs), which are colloquially known as “patent trolls” and sometimes referred to as “non-practicing entities” (NPEs)... Read More »

Attention CEO’s: You Are In The Software Business. Now What?

Jim Zemlin | | October 4, 2012

Whether you’re Nissan or Toyota, Walmart or Nordstrom, NYSE or NASDAQ, you are in the software business. Every company today, regardless of whether or not they’re a “technology” company, is in the business of building software. Today’s consumers demand it.

Read More »

Embracing Open-Source Biotech: DNA Freeware May Out-Innovate Patented Genes

Carole Jacques | Lux Research | August 28, 2013

...biotechnology companies need to incorporate open-source into their innovation plans in order to succeed in the emerging landscape, according to Lux Research. Read More »

Federal Budget Politics: Where’s Health IT Research Going?

Anthony Brino | Government Health IT | September 13, 2012

Amidst so much political talk of budget deficits and the role of government, the greater science community is wondering what a Mitt Romney/Paul Ryan budget would mean for federal research funding. Read More »

GSK Expands Open-Source Research Project In TB

Staff Writer | PMLIVE | October 11, 2012

GlaxoSmithKline (GSK) has screened its entire pharmaceutical compound library of more two million compounds and identified about 200 hits with potential against tuberculosis (TB), which it will make available to external research teams as part of its drive towards an 'open innovation' approach to R&D. Read More »

How Fledgling Start-Ups Can Benefit from Accelerator Programmes

Giovanni Rizzo | Medical Plastics News | July 7, 2017

Start-ups in the life science sector are a source of invaluable innovation, entrepreneurial spirit and ultimately, important developments that could improve patient health. It is through new ideas that the sector can face current and future challenges, such as an ageing population, the need to invest in new-generation, digitalised technology, and a rise in patient demand of service and value for money. But data shows that 90% of all start-ups fail within the first year, a worrying statistic considering the wealth of advantages that innovation can bring to the life sciences industry...

Read More »

Less Neglect, More Openness: Two ‘Grand Experiments’ In Health Innovation

Bernard Pécoul | | November 28, 2013

Commemorating the 10th Anniversaries of PLOS and the Drugs for Neglected Diseases initiative (DNDi), Bernard Pécoul, Executive Director of DNDi, discusses the innovative journeys of the organisations. Read More »

Medicines Shouldn't Be A Luxury - Médecins Sans Frontières

Staff Writer | MSF Access | January 28, 2015

What if the medicines that could save your life cost a hundred times what you earn in a year?  Many people in developing countries can’t get hold of the treatment they need to stay alive and healthy...

Read More »

Nurturing Health Innovation In Africa: 13 Ways To Boost Research

Rachel Banning-Lover | The Guardian | September 3, 2014

...One continent-wide approach to investing in research in Africa will not suit the needs of every country. In 2009, approximately one third of all African scientists or people with engineering degrees were working and living abroad...

Read More »

Opening Up The Indian Rare Disease Market: An Interview With ORD India

Cameron | Total Orphan Drugs | March 20, 2014

We here at Total Orphan Drugs, as part of this month’s focus on emerging markets for the orphan drug industry, have been speaking to Harsha K Rajasimha of the newly formed Organization for Rare Diseases India (ORDI).  With a rare disease population estimated to be around 72,611,605 (more than the US and EU rare disease populations combined) the need for orphan treatments is huge, and with little in place so far, India represents a lucrative market to developers and pharma looking to expand their orphan operations.

Read More »

Patient Engagement, Data Liberation And Portability

Christine Årdal and John-Arne Røttingen | PLOS Neglected Tropical Diseases | September 20, 2012

Open source drug discovery can be an influential model for discovering and developing new medicines and diagnostics for neglected diseases. It offers the opportunity to accelerate the discovery progress while keeping expenditures to a minimum by encouraging incremental contributions from volunteer scientists.
Read More »

PLOS & DNDi Launch A New Collection Celebrating A Decade Of Open Access And NTD R&D

Rhona MacDonald | | December 5, 2013

As part of a collaborative initiative, PLOS and the Drugs for Neglected Diseases initiative (DNDi) are delighted to launch a special Collection—PLOS & DNDi: a decade of Open Access and Neglected Tropical Diseases R&D—to coincide with a joint event at the Institut Pasteur in Paris celebrating the 10 year anniversary of DNDi... Read More »

Prescribable Mobile Apps Huge Threat For Pharma

Dave Chase | Forbes | May 14, 2012

With the proliferation of mHealth apps, it was only a matter of time before healthcare providers would start prescribing apps as soon as apps proved to be as or more effective than prescription drugs. Read More »

Seven Bridges Introduces Open Source Cancer Genomics Workflow

John Otrompke | Bio IT World | August 20, 2014

Seven Bridges, a Cambridge company that builds tool to help scientists process genomic data, has created a cloud-based workflow for analyzing cancer genomes. The workflow was presented at the Biology of Genomes conference at Cold Spring Harbor in May...

Read More »

VC Market Drying Up For Emerging Medtech Firms

Julie Bird | FierceHealthIT | October 4, 2012

Start-up medical-technology companies are finding it harder to raise venture capital, thanks to "an anemic IPO market and ever-more selective buyers," Ernst & Young says in a new market report. Read More »